Abstract. Breast cancer is one of the most common malignancies diagnosed in women and it is increasing in incidence. *Siegesbeckia glabrescens* (SG) has been used in traditional oriental medicine to treat cardiovascular diseases such as hypertension and angina pectoris. This study examined whether or not SG could induce apoptosis in human breast carcinoma cells. The treatment of estrogen-receptor (ER)-positive (MCF-7) and ER-negative (MDA-MB-231) cells with a variety of SG concentrations (0-1.0 mg/ml) resulted in a dose-dependent sequence of events that were marked by apoptosis. Furthermore, this apoptosis was accompanied by the cleavage of procaspase-9 and -3, and poly(ADP-ribose) polymerase (PARP) in the MCF-7 cells, and procaspase-8 and -3 and PARP in the MDA-MB-231 cells. Although, the SG-induced apoptosis was associated with a decrease in the level of Bcl-2 mRNA expression and an increase in the level of Bax mRNA expression in MCF-7 cells, there was no detectable change in the MDA-MB-231 cells. This suggests that SG might exert anti-proliferative action in human breast carcinoma cells via two different apoptotic pathways, namely an intrinsic signal in MCF-7 cells and an extrinsic signal in MDA-MB-231 cells. Therefore, regardless of the ER status, SG might be a promising pro-apoptotic agent for treating breast cancer.

Introduction

Breast cancer is the most common malignancy in American, northwestern European and South Korean women with an increasing incidence in industrialized nations. Approximately 60% of diagnosed breast cancers are estrogen receptor (ER)-positive (1). ER-positive breast cancers generally have a better prognosis and often respond to anti-estrogen therapy, which is the first successful treatment that targets a specific protein, ER (2,3). Unfortunately, ER-negative breast cancer is more aggressive and generally unresponsive to anti-estrogens (4).

Apoptosis is essential for balancing breast epithelial cell homeostasis with cell proliferation. It is defined as genetically programmed cell death and occurs in healthy breast cells at rates that vary during the estrus cycle as a response to hormonal changes (5). Mutations in apoptotic regulatory mechanisms can result in an increase in the number of cells, and the preservation of these genetically altered cells is the initial stage in tumorigenesis (6). Many studies strongly suggest the induction of apoptosis as the means by which chemotherapeutic drugs kill the target breast cancer cells (7,8). The efficacy of these unrelated chemotherapeutic drugs could be modified according to the biochemical alterations that make the cells more or less susceptible to apoptosis (9,10).

There are reports that suggest herbal medicines might be effective against cancer and reduce the level of resistance to chemotherapy (11-13). *Siegesbeckia glabrescens* (SG) has been used in traditional oriental medicine for centuries to treat hypertension, osteoporotic fractures, quadriplegia, paralysis, and hemiplegia. In addition, SG has been shown to have anti-allergic activity by inhibiting the production of immunoglobulin (Ig) E in lipopolysaccharide-stimulated murine whole spleen cells and human IgE-bearing B cells (14). However, the anti-tumor activity and mechanisms of SG on human cancer cells have never been reported.

Therefore, this study examined whether or not SG could inhibit the growth of ER-positive (MCF-7) and ER-negative (MDA-MB-231) human breast carcinoma cells, regardless of their ER status. In addition, the biochemical steps linking SG to the apoptotic process in these cells were investigated.

Materials and methods

Preparation of *Siegesbeckia glabrescens* (SG) extract. The water extract was prepared by mixing 200 g SG with 1,000 ml of distilled water and heating the mixture to 70˚C under reflux for 90 min. The extract was then filtered through a filter paper (Advantec no. 2; Toyo Roshi Kaisha, Japan), and the filtrate was concentrated to approximately 100 ml using a rotary evaporator (Heidolph, Germany) at 70˚C under vacuum. The residue was then freeze-dried (Hetosicc, Denmark). The yield of the dried extract was approximately 22.28 g/l.
Cell lines and culture. Human MCF-7 and MDA-MB-231 breast carcinoma cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and Korean Cell Line Bank (Seoul, South Korea), respectively. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Lab., Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Morgate, Australia), 2 mM L-glutamine and 1% penicillin-streptomycin (Gibco) in a humidified incubator (5% CO2 in air at 37˚C).

Cell viability assay. The cells (10x10^4 cells/ml) were seeded into a 96-well plate. After 24 h, the cells were washed with PBS and cultured with serum-free media for a further 20 h. The cells were then treated with 0, 0.1, 0.3, 0.5, 0.8 and 1.0 mg/ml SG for 24 h. At the end of the assay time period, 50 μl of sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT, Roche Diagnostics, Germany) was added to each well to measure cell viability. After 4-h incubation, the absorbance was measured on an ELISA reader (Bio-Tek Instruments, Winooski, VT, USA) at a wavelength of 490 nm. The background control wells containing the same volume of complete culture medium without cells were also analyzed. The percentage of cell survival was defined as the relative absorbance of untreated cells divided by that of treated cells.

Flow cytometric analysis. After the SG treatment, the cells were collected, washed with cold PBS, and fixed in 75% ethanol at 4˚C for 30 min. The DNA content of the cells was measured using a DNA staining kit (CycleTest™ Plus kit; Becton-Dickinson, San Jose, CA, USA). The propidium iodide (PI)-stained nuclear fractions were obtained according to the kit protocol. The fluorescence intensity was determined using a FACScan flow cytometer and analyzed by CellQuest software (Becton-Dickinson).

Western blot analysis. After the SG treatment, the cells (5x10^5 cells/ml in 6-well plate) were lysed in an RIPA buffer (10% NP-40 containing 20 μg/μl Na2VO4, 10 μg/μl leupeptin and 10 μg/μl aprotinin) and placed on ice for 30 min. After centrifugation at 12,000 x g for 10 min, the supernatants were collected, and the total protein content was determined using a Lowery protein assay reagent. Equivalent amounts of protein were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE, 7.5-12.5%) and transferred to nitrocellulose.
membranes. The polyclonal antibodies of procaspase-8, -9, and -3 and poly(ADP-ribose) polymerase (PARP) were used as the primary antibodies (Cell Signaling, Beverly, MA, USA). Each protein was detected using enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech, UK) reagents, and the actin polyclonal antibody was used as the internal control.

cDNA preparation and PCR. RNA was isolated from the treated and untreated cells (5x10^5 cells/ml in a 6-well plate) using Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH, USA), which is an RNA/DNA/protein isolation reagent. The cDNA was then synthesized by reverse transcriptase (RT) with 0.5 μg of oligo dT, 20 units of AMV reverse transcriptase, 1 μg of the total cellular RNA, 4 μl of 5X RT buffer, 0.5 mM each dNTP, and 11 μl of DEPC. The 20 μl reaction mixtures underwent incubation at 65˚C for 5 min, followed by 42˚C for 1 h, heating to 95˚C for 5 min, and rapid chilling on ice. The presence of Bcl-2 and Bax was determined by a polymerase chain reaction (PCR) (MJ Research, Reno, NV, USA) using sequence-specific primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control to ensure that equal amounts of RNA were used. PCR was carried out in a 1X reaction buffer containing 0.5 mM dNTP, 10 pmole of the sense and anti-sense

Figure 2. Phase-contrast micrographs of the SG-treated MCF-7 (A) and MDA-MB-231 (B) cells. The cells were treated with indicated concentrations of SG for 24 h. A typical result from three independent experiments is shown (original magnification, x100).

Figure 3. Induction of apoptotic bodies and DNA fragmentation by SG treatment in the MCF-7 and MDA-MB-231 cell lines. (A) Fluorescence microscopic analysis of DAPI staining of MCF-7 and MDA-MB-231 was performed as described in Materials and methods. The cells were examined by fluorescence microscopy. (B) SG (0.3 mg/ml) induced DNA fragmentation in the MCF-7 and MDA-MB-231 cells. The method for extracting cellular DNA and its electrophoresis on 1% agarose gels is described in Materials and methods. These results are representative of five (MCF-7) and six (MDA-MB-231) independent experiments.
primers for Bcl-2, Bax and GAPDH, 0.5 μl cDNA, and 5 units of Taq DNA polymerase in a 25 μl reaction mixture. The PCR profile consisted of 35 (Bcl-2), 32 (Bax), 28 (GAPDH) cycles at 95˚C for 5 min, 95˚C for 20 sec, 59˚C for 40 sec, 72˚C for 1 min and a final extension at 72˚C for 10 min. The PCR products were analyzed on 1.5% agarose gel and stained with EtBr. The following primer sequences were used: Bcl-2 forward, 5'-GACAACCGGGAGATAGTGAT-3' and reverse, 5'-ACTCAAAGAAGGCCACAATCC-3'; Bax forward, 5'-ACCAAGAAGCTGAGCGAGTGTC-3' and reverse 5'-AGAAAGATGGTCACGGTCTGCC-3'; GAPDH forward, 5'-CCATGGAGAAGGCTGGGG-3' and reverse, 5'-CAAAGTTGTCATGGATGACC-3'.

Bands on the gel were scanned as digitalized images, and the areas under the peaks were calculated by densitometric analysis using a computerized digital imaging system. The areas are reported in arbitrary units. The relative expression level was calculated by comparing the expression level of the sample with that of the internal standard (GAPDH). At least a 2-fold decrease in the relative expression level was considered to be reduced, which was verified by repeat RT-PCR assays.

Statistics. Data are expressed as mean ± SD. The statistical comparisons were made using a sigma plot. Significant differences (P<0.05, P<0.005, and P<0.0005) between the means of the control and SG-treated cells were analyzed using a Student's t-test.

Results

Cell growth inhibition and morphological changes by SG treatment. The MCF-7 and MDA-MB-231 cell lines were treated with 0-1.0 mg/ml SG for 24 h to determine whether SG caused a decrease in the number of cells. Fig. 1 shows that the SG treatment inhibited cell growth in a dose-dependent manner, as determined by the XTT assay. At 24 h, the maximum effect was observed with 0.8 mg/ml SG, which inhibited the proliferation of MCF-7 and MDA-MB-231 cells by 67.7% (Fig. 1A) and 75.7% (Fig. 1B), respectively. This anti-proliferative effect of the SG treatment was associated with nuclear and cytosol shrinkage (Fig. 2), which were determined to be apoptotic events (16).

SG treatment induced apoptotic bodies and DNA fragmentation. The nuclear morphological changes associated with apoptosis were analyzed using DAPI staining (15). Fig. 3A revealed the presence of fragmented nuclei characteristic of apoptosis after the SG treatment. In addition, a ladder-like pattern of DNA fragmentation using agarose gel electrophoresis was observed at 10 and 720 min after the SG treatment in MCF-7 and MDA-MB-231 cells, respectively (Fig. 3B). We next analyzed the amount of sub-G1 DNA, which contained less DNA than G1 cells, to quantify the degree of apoptotic cells. Flow cytometric analysis indicated that the SG treatment increased accumulation in the sub-G1 phase in a time-dependent manner (Fig. 4). Overall, these results demonstrate that the cytotoxic effect observed in response to the SG treatment is associated with the induction of apoptotic cell death.

Effect of SG on procaspase-8, -9, and -3 and PARP cleavage. Currently, there are two known pathways that activate the caspase cascade, the intrinsic and extrinsic pathways. Following the initial activation of caspase-9 and -8 in the intrinsic and extrinsic pathways (17), respectively, each caspase cleaves procaspase-3, which normally exists as a 32-kDa inactive precursor and its active form, a 17-kDa fragment. Once activated, caspase-3 proteolytically cleaves the 116-kDa PARP protein into an 85-kDa fragment, which is considered to be a biochemical characteristic of apoptosis. Western blot analysis results showed that SG induced the down-regulation of procaspase-3, which normally exists as a 32-kDa inactive precursor and its active form, a 17-kDa fragment. Once activated, caspase-3 proteolytically cleaves the 116-kDa PARP protein into an 85-kDa fragment, which is considered to be a biochemical characteristic of apoptosis. Western blot analysis results showed that SG induced the down-regulation of procaspase-8 in MDA-MB-231 cells, but not in MCF-7 cells. On the other hand, procaspase-9 was down-regulated in MCF-7 cells, but not in MDA-MB-231 cells (Fig 5). SG induced the proteolytic cleavage of procaspase-3 and PARP into their respective active forms, as shown in Fig. 5.

SG changed the ratio of Bcl-2 and Bax mRNA expression. Among Bcl-2 family members, the Bcl-2 and Bax expression ratio might be a key factor in regulating the apoptotic process (18,19). Therefore, the MCF-7 and MDA-MB-231 cells were treated with 0.5 mg/ml of SG at the times shown in Fig. 6. RT-PCR analysis was used to determine the ratio of Bcl-2 and Bax mRNA expression. As shown in Fig. 6, the SG treatment decreased the level of Bcl-2 mRNA expression in
MCF-7 cells, but increased the level of Bax expression. However, in MDA-MB-231 cells, the SG treatment had little effect on the levels of Bcl-2 and Bax expression.

Discussion

Endocrine therapies, which were first used more than 100 years ago, are the most effective treatments for ER-expressing breast cancers. Selective ER modulators, such as tamoxifen, bind the ER, partially blocking its activity (20). Ovarian ablation, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors reduce the estrogen level and inhibit the ligand-induced activation of the ER (21,22). Steroidal anti-estrogens, such as fulvestrant, bind the ER, block its function more completely, and induce receptor degradation (23). Although many therapies have been developed, most are restricted to ER-expressing breast cancers.

Siegesbeckia glabrescens (SG) is a herbal medicine widely used in South Korea for detoxification and treating arthritis and fever (14). This study first reported the effect of SG in inhibiting cell growth in ER-positive MCF-7 and ER-negative MDA-MB-231 cells. SG induced apoptosis in MCF-7 and
MDA-MB-231 cells, which was determined by a loss of cell viability, nuclear shrinkage, and apoptotic body formation, as confirmed by the TdT assay, DAPI staining and internucleosomal DNA fragmentation. However, these effects were not observed in healthy human umbilical vein endothelial cells (data not shown). This suggests that SG specifically inhibits cell growth and induces apoptotic cell death in breast cancer cell lines.

Apoptosis is essential for the development and maintenance of life. It is currently defined as a discrete sequence of morphological changes leading to cell death with extensive dsDNA cleavage accompanied by chromat in compaction and segregation along the nuclear membrane (5,6). It has been reported that apoptosis contributes to cell death in tumors treated with various anti-carcinoma agents. Moreover, most developed chemotherapeutic agents (Prodigiosin, Cimicifuga racemosa, Antrodia camphorata, et al), which originate from natural products, reportedly induce apoptosis in breast cancer cells (10,24,25).

Currently, there are two known pathways that can activate the caspase cascade. The intrinsic pathway involves the Bcl-2 family of proteins and the release of cytochrome c from the mitochondria (26-28). Once released, cytochrome c binds to the Apaf-1 adaptor protein, which then activates procaspase-9 in a dATP-dependent reaction leading to procaspase-3 activation. The extrinsic pathway is independent of the mitochondria and is induced by the death receptor-protein complexes that cleave procaspase-8 (29). The cleavage and activation of caspase-8 initiates the caspase cascade. Following the initial induction, the intrinsic and extrinsic pathways merge at the caspase-3 level. At the onset of apoptosis, activated caspase-3 degrades the PARP protein (30).

This study examined the apoptotic pathways resulting from the SG treatment in human MCF-7 and MDA-MB-231 breast carcinoma cell lines. The results showed that SG induced apoptosis via the cleavage of procaspase-9 and -3 and PARP in MCF-7 cells, and cleavage of procaspase-8 and -3 and PARP in MDA-MB-231 cells. This suggests that, after the addition of SG, the extrinsic pathway might be involved in MCF-7 apoptosis, and the intrinsic pathway plays a role in MDA-MB-231 apoptosis.

The Bcl-2 family consists of a number of both anti-apoptotic (Bcl-2, Bcl-XL, Mcl-1, Bfl-1/A1, Bcl-W and Bcl-G) and proapoptotic (Bax, Bak, Bok, Bad, bid, Bik, Bim, Bel- XS, Krk, Mtd, Nip3, Noxa and Bel-B) proteins (31,32). Expression and dimerization of the Bcl-2 family proteins influence cellular sensitivity to apoptosis by regulating the release of cytochrome c, which precedes caspase activation (18,19). In this study, SG dramatically decreased the level of Bcl-2 mRNA expression and increased the level of Bax mRNA expression in MCF-7 cells. However, there was no detectable change in the levels of Bcl-2 and Bax mRNA expression in MDA-MB-231 cells.

In conclusion, SG has an anti-proliferative effect in both ER-positive MCF-7 and ER-negative MDA-MB-231 cells by inducing apoptosis. The molecular mechanisms of the apoptotic effect by SG are: i) degradation of procaspase-9 and -3 and PARP in MCF-7 cells; ii) cleavage of procaspase-8 and -3 and PARP in MDA-MB-231 cells; iii) a decrease in the level of Bcl-2 expression and an increase in the level of Bax mRNA expression in MCF-7 cells; and iv) no detectable change in the levels of Bcl-2 and Bax mRNA expression in MDA-MB-231 cells. These results highlight SG as a promising chemosensitive agent, particularly for estrogen receptor-negative breast cancers, which have a poorer prognosis and shorter survival. However, further investigation is needed to determine the active components in SG along with the mechanisms for its action on human breast carcinomas.

References


